ClinicalTrials.gg
Not yet recruitingNCT05991271Updated Aug 18, 2023

Venus-Vitae Pivotal Study Smart-Align Study

An interventional study of Venus-Vitae Transcatheter Heart Valve System in Aortic Valve Stenosis, sponsored by Venus MedTech (HangZhou) Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Venus MedTech (HangZhou) Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose is to evaluate the safety, effectiveness and performance of Venus-Vitae Transcatheter Heart Valve System in patients with severe aortic stenosis.

Read the detailed description

This trial is a prospective, multi-center, non-randomized interventional study to evaluate the safety, effectiveness and performance of the Venus-Vitae Transcatheter Heart Valve System in patients with severe aortic stenosis. Clinical visits will be scheduled at screening, pre-discharge, 30 days, 6 months, 12 months and annually thereafter to 5 years.

02

Conditions studied

  • Aortic Valve Stenosis
03

In context

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

This study's planned enrollment of 150 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Venus MedTech (HangZhou) Inc. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Patients with the symptoms of severe aortic stenosis
  3. Severe aortic stenosis (AS, grade 3+), defined as AVA ≤ 1 cm2 (AVAi ≤ 0.6 cm2/m3) or Vmax ≥ 4.0 m/s or MPG ≥ 40 mmHg determined by echocardiography
  4. Patients deemed for cardiac intervention by a heart team
  5. Patients of all surgical risk categories can be enrolled in this study, but should follows local medical practices and regulatories.
  6. Patients or their legal reprensentatives are willing to participate in the study and provide written , and agree to follow the follow-up requirements

Exclusion criteria

Exclusion Criteria:

A subject meeting any of the following criteria shall be excluded:

Co-morbidities

  1. Previous mechanical or biological aortic valve replacement
  2. Untreated mitral, tricuspid or pulmonary valve diseases requiring procedural intervention
  3. Acute myocardial infact within 30 days prior to index procedure
  4. Untreated clinical significant coronary artery disease requiring revascularization
  5. Any therapeutic invasive cardiac procedure performed within 30 days (or drug-eluting coronary stent/scaffold implant within 6 months)
  6. Sever symptomatic carotid artery stenosis
  7. Stroke or within 3 months or Modified Rankin Scale ≥ 4 disability
  8. Chronic kidney disease (\<30 mL/min/1.73m2)
  9. Haemotologic disorders: Leukopenia (WBC \< 3000 cell/mL), anemia ( \< 9 g/dL), thrombocytopenia (Plt\< 50,000 cell/mL), or any known blood clotting disorder, deemed after consultation with Haematooncology specialists
  10. Severe right heart dysfunction Anatomical
  11. \< 20%
  12. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
  13. Inappropriate anatomy for femoral introduction and delivery of study device
  14. Native aortic valve geometry and size unfavorable for study device anchoring General
  15. Haemodynamics instability requiring inotropic support or intra-aortic balloon pump (IABP) or other hemodynamic support device, or any mechanical heart assistance
  16. Known or to antiplatelet, antithrombotic medications, or cobalt-chromium leading to be unable to undergo index procedure per physicians' judgement
  17. ≤ 1 year due to noncardiac reasons
  18. Active infection requiring antibiotic therapy including infective endocarditis
  19. Planned relevant concomitant procedure within 30 days post index procedure
  20. Pregnant, breastfeeding or intend to become pregnant within 1 year
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    procedure

    implant valve by TAVR

    Device: Venus-Vitae Transcatheter Heart Valve System

Interventions

  • DeviceVenus-Vitae Transcatheter Heart Valve System

    The Venus-Vitae THV is comprised of balloon-expandable and radiopaque cobalt-chromium alloy frame, porcine pericardium tri-leaflet, porcine pericardium inner skirt, polyurethane outer skirt, PTFE assembly sutures, and three radiopaque gold markers (Figure 1). The valve utilizes Venus Endura technology and stored in a non-aqueous condition.

06

What researchers measure

Primary outcomes

  1. The rate of deaths at the one-year follow-up visit post procedure

    All-cause mortality (The rate of deaths at the one-year follow-up visit post procedure)

    Time frame: 1 Years

  2. Acceptable Hemodynamic Performance at 30 days

    Acceptable Bio-prosthesis Hemodynamic Performance at 30 days, defined as: * Mean gradient \< 20mmHg * Less than moderate aortic regurgitation (perivalvular and transvalvular)

    Time frame: 30 Days

Secondary outcomes

  1. Occurrence of the following adverse events echocardiogram during follow-up

    Occurrence of the following adverse events echocardiogram during follow-up (The rate of follow events during the follow-up) * All-cause mortality * All stroke * Life-threatening bleeding * Acute MI * Heart failure hospitalizations * New permanent pacemaker implantation * Major vascular complication * Acute kidney injury * Aortic valve re-intervention (surgical or transcatheter) * Valve thrombosis * Structural valve deterioration

    Time frame: 5 Years

  2. Technical success is defined as the following

    Technical success (at exit from procedure room) (VARC-3\[1\]) (The rate of Technical success at the Procedure) * Freedom from mortality * Successful access, delivery of the device, and retrieval of the delivery system * Correct positioning of a single prosthetic heart valve into the proper anatomical location * Freedom from surgery or intervention related to the device or a major vascular or access-related, or cardiac structural complication

    Time frame: During the Procedure

  3. The rate of device success is defined as the following

    Device success (in-hospital) (VARC-3\[1\]) (The rate of device success during the in-hospital) * Freedom from mortality * Freedom from surgery or intervention related to the device or a major vascular or access-related or cardiac structural complication * Intended performance of the valve (mean gradient \< 20 mmHg, peak velocity \<3 m/s, and less than moderate aortic regurgitation)

    Time frame: Up to 1 week

  4. The rate of acceptable valve function at pre-discharge by echocardiogram defined as the following:

    Acceptable valve function at pre-discharge by echocardiogram (The rate of follow events during the follow-up) * Freedom from moderate or greater patient-prosthesis mismatch (PPM) * MPG \<20mmHg * Freedom from moderate or greater regurgitation (transvalvular and paravalvular) * Freedom from reoperation or intervention

    Time frame: Up to 1 week

  5. The rate of freedom from severe coronary overlap assessed by post-implant angiogram

    Freedom from severe coronary overlap assessed by post-implant angiogram

    Time frame: immediately after the procedure

  6. The rate of freedom from mild or greater commissure misalignment assessed by post-implant angiogram and/or 30-day CT

    Freedom from mild or greater commissure misalignment assessed by post-implant angiogram and/or 30-day CT (post-implant 30-day CT scan is not mandatory for each subjects)

    Time frame: 30-Days

  7. The rate of freedom from mild or greater PVL by echocardiogram during follow-up

    Freedom from mild or greater PVL by echocardiogram during follow-up

    Time frame: 5 Years

  8. New York Heart Association (NYHA) classification during follow-up

    New York Heart Association (NYHA) classification during follow-up

    Time frame: 5 Years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Dec 2024, 14 months later.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 14 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Aug 14, 2023
StartEst.
Oct 31, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 30, 2029
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05991271
Lead sponsor
Venus MedTech (HangZhou) Inc.
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Oct 31, 2023 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Aug 18, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion